Fæno- eller genotype test for dihydropyrimidindehydrogenase-mangel før fluoropyrimidinbehandling

Stig Ejdrup Andersen, Niels Herluf Paulsen, Per Pfeiffer, Camilla Qvortrup, Per Damkier

Publikation: Bidrag til tidsskriftReviewForskningpeer review


Some patients may have partial or complete deficiency of dihydropyrimidin dehydrogenase (DPD) and be more likely to experience severe toxicity with 5-fluorouracil. Since the spring of 2020, the Danish Medicines Agency has recommended genotype or phenotype testing before treatment with a fluoropyrimidine, but the most appropriate test strategy is debated. In this review, we present polymorphisms in the genes coding for DPD and summarise the evidence for DPD-enzyme deficiency testing and pharmacokinetic guided dosing.

Bidragets oversatte titelPhenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine
TidsskriftUgeskrift for laeger
StatusUdgivet - 8 feb. 2021


  • Antimetabolites, Antineoplastic/therapeutic use
  • Dihydropyrimidine Dehydrogenase Deficiency/drug therapy
  • Dihydrouracil Dehydrogenase (NADP)/genetics
  • Fluorouracil/adverse effects
  • Genotype
  • Humans
  • Phenotype


Udforsk hvilke forskningsemner 'Fæno- eller genotype test for dihydropyrimidindehydrogenase-mangel før fluoropyrimidinbehandling' indeholder.